Nektar Therapeutics(NKTR)
SAN FRANCISCO, CA
BiotechnologyFocus: Small Molecules, Biologics
Nektar Therapeutics is a life sciences company focused on Small Molecules, Biologics.
OncologyInfectious DiseasesImmunologyDermatologyMetabolic Diseases
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
TAK-659
Lymphoma, Non-HodgkinClinical Trials (1)
NCT03772288A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Phase 1LY3471851
Dermatitis, AtopicPlacebo
PsoriasisNKTR-255
Multiple MyelomaClinical Trials (1)
NCT04136756NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Phase 1LY3471851
HealthyNKTR-181
Moderate to Severe Chronic PainClinical Trials (1)
NCT03802227A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
Phase 1Cyclophosphamide
Recurrent Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT05359211NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Phase 1NKTR-214
Advanced CancerLY3471851
HealthyBempegaldesleukin
Covid-19Clinical Trials (1)
NCT04646044A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
Phase 1LY3471851
HealthyLY3471851
Systemic Lupus ErythematosusNivolumab
Renal Cell CarcinomaLY3471851
Healthy145 mg/m2 NKTR 102
Advanced or Metastatic Solid Tumors in Patients With Hepatic ImpairmentClinical Trials (1)
NCT01991678A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
Phase 1Bempegaldesleukin
Metastatic MelanomaClinical Trials (1)
NCT04955262A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Phase 1Phase 1
Clinical Trials (1)
NCT05676749C-TIL051 in Non-Small Cell Lung Cancer
Phase 1NKTR-102
Advanced CancerClinical Trials (1)
NCT01976143A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
Phase 1Phase 1/2
Nivolumab
EpendymomaPhase 1/2
Clinical Trials (1)
NCT03548467A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT04616196Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT02869295A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Phase 1/2Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
MelanomaNKTR-214
Non-Small Cell Lung CancerClinical Trials (1)
NCT03138889Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
Phase 1/2NKTR-262
MelanomaClinical Trials (1)
NCT03435640REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Phase 1/2Phase 2
NKTR-214
Head and Neck CancerClinical Trials (1)
NCT04936841Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
Phase 2Dronabinol MDI
Migraine With AuraClinical Trials (1)
NCT00123201Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
Phase 2NKTR-181
Osteoarthritis of the KneeClinical Trials (1)
NCT01619839A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain
Phase 2Pegylated Irinotecan
Stage IV Non-small Cell Lung Cancer (NSCLC)Clinical Trials (1)
NCT02312622Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Phase 2Laboratory Biomarker Analysis
Recurrent Small Cell Lung CarcinomaClinical Trials (1)
NCT01876446Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Phase 2Rezpegaldesleukin
Alopecia AreataClinical Trials (1)
NCT06340360A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Phase 2NKTR-102 100 mg/m2
TumorClinical Trials (1)
NCT00598975NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
Phase 2NKTR-255
Lung CancerClinical Trials (1)
NCT05632809REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
Phase 2Etirinotecan pegol
Anaplastic AstrocytomasClinical Trials (1)
NCT01663012Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Phase 2aerosolized vancomycin or gentamicin
Ventilator Associated PneumoniaClinical Trials (1)
NCT00396578Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation
Phase 2NKTR-102
TumorClinical Trials (1)
NCT00802945Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
Phase 2Amikacin inhalation solution
PneumoniaPhase 2
NKTR-102
Colorectal CancerClinical Trials (1)
NCT00856375NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Phase 2NKTR-102 145 mg/m2
Malignant Solid TumorClinical Trials (1)
NCT01457118An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Phase 2Amikacin
PneumoniaNKTR-102 q14d
TumorClinical Trials (1)
NCT00806156Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
Phase 2LY3471851
Systemic Lupus ErythematosusLY3471851
Colitis, UlcerativeBempegaldesleukin
Urinary Bladder NeoplasmRezpegaldesleukin
Moderate to Severe Atopic DermatitisClinical Trials (1)
NCT06136741A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase 2NKTR-255 at 1.5 µg/kg
Non-Hodgkin LymphomaClinical Trials (1)
NCT05664217NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Phase 2/3Bempegaldesleukin
Metastatic Head and Neck CancerOpen Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 30 clinical trials
SEC Filings: 2 available
Financials (FY2025)
Revenue
$98M9%
R&D Spend
$121M(123%)6%
Net Income
-$119MCash
$44MVisa Sponsorship
H-1B Petitions (FY2023)
0
Approved
1
Denied
0%
Rate
Source: USCIS H-1B Employer Data Hub